Immuneering Announces Inclusion in the Russell 2000® Index

NEXT STORY
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
PREV STORY
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Smart Syringes Market Is Expected To Gain From Enhanced Need to Prevent Hospital Or Clinic-acquired Infections Till 2024: Grand View Research, Inc.

San Francisco, July 06, 2016 (GLOBE NEWSWIRE) -- The global smart syringes market is expected ...

author_avatar
NASDAQ Market News

Global qPCR and dPCR Instrumentation Market Report 2016-2019 & 2024: Increasing Incidence and Prevalence of Cancer – A Grim Reality Driving Demand for qPCR and dPCR

Dublin, Feb. 07, 2019 (GLOBE NEWSWIRE) -- The "qPCR and dPCR Instrumentation - Market ...

author_avatar
NASDAQ Market News

CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

author_avatar
NASDAQ Market News